75 related articles for article (PubMed ID: 3842636)
1. Myelosuppression occurring after receiving tamoxifen for breast cancer. International Adjuvant Therapy Organisation.
Br J Radiol; 1985 Dec; 58(696):1220. PubMed ID: 3842636
[No Abstract] [Full Text] [Related]
2. [Adjuvant therapy of breast cancer with tamoxifen and endometrial carcinoma].
Mignotte H; Sasco AJ; Lasset C; Saez S; Rivoire M; Bobin JY
Bull Cancer; 1992; 79(10):969-77. PubMed ID: 1292764
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
4. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
6. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
7. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
Gianni L; Panzini I; Li S; Gelber RD; Collins J; Holmberg SB; Crivellari D; Castiglione-Gertsch M; Goldhirsch A; Coates AS; Ravaioli A;
Cancer; 2006 Feb; 106(3):505-13. PubMed ID: 16369994
[TBL] [Abstract][Full Text] [Related]
8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
9. Nephrotic syndrome and adjuvant treatment with tamoxifen for early breast cancer. Case report and review of the literature.
Lauro S; Lalle M; D'Andrea MR; Vecchione A; Frati L
Anticancer Res; 1994; 14(5B):2171-2. PubMed ID: 7840519
[TBL] [Abstract][Full Text] [Related]
10. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
[TBL] [Abstract][Full Text] [Related]
11. Uterine pleomorphic rhabdomyosarcoma in a patient receiving tamoxifen therapy.
Okada DH; Rowland JB; Petrovic LM
Gynecol Oncol; 1999 Dec; 75(3):509-13. PubMed ID: 10600318
[TBL] [Abstract][Full Text] [Related]
12. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation.
Lancet; 1985 Apr; 1(8433):836-40. PubMed ID: 2858709
[TBL] [Abstract][Full Text] [Related]
13. Carcinosarcoma arising in uterine didelphys after tamoxifen therapy for breast cancer: a case report.
Suprasert P; Khunamornpong S
J Med Assoc Thai; 2010 May; 93(5):608-12. PubMed ID: 20524448
[TBL] [Abstract][Full Text] [Related]
14. Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer.
Boele FW; Schilder CM; de Roode ML; Deijen JB; Schagen SB
Menopause; 2015 Jan; 22(1):17-25. PubMed ID: 24977455
[TBL] [Abstract][Full Text] [Related]
15. [Tamoxifen in breast cancer: viewpoint of the gynecologist].
De Muylder X
Acta Clin Belg; 1992; 47(3):178-84. PubMed ID: 1332348
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and adjuvant tamoxifen treatment in breast cancer patients.
Boehm DU; Lebrecht A; Eckhardt T; Albrich S; Schmidt M; Siggelkow W; Kandelhardt E; Koelbl H
Eur J Cancer Care (Engl); 2009 Sep; 18(5):500-6. PubMed ID: 19490009
[TBL] [Abstract][Full Text] [Related]
17. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
18. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study.
Debess J; Riis JØ; Engebjerg MC; Ewertz M
Breast Cancer Res Treat; 2010 May; 121(1):91-100. PubMed ID: 20306129
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring of postmenopausal women treated with tamoxifen for breast carcinoma].
Epifani S; Lattarulo S; Maiorino R; Fabiano G
G Chir; 2000; 21(6-7):310-2. PubMed ID: 10916956
[TBL] [Abstract][Full Text] [Related]
20. [Endometriosis in tamoxifen therapy].
Fuith LC; Pflanzl W
Geburtshilfe Frauenheilkd; 1995 Jun; 55(6):354-5. PubMed ID: 7657147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
